BRIEF published on 12/23/2024 at 21:09, 1 year 7 months ago Succès de l'offre publique de TME Pharma N.V. Actionnaires Augmentation De Capital Cancer NOX-A12 Stratégies Financières
BRIEF published on 12/23/2024 at 21:09, 1 year 7 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
PRESS RELEASE published on 12/23/2024 at 21:04, 1 year 7 months ago Informations privilégiées / Autres communiqués TME Pharma réussit son offre publique de 2,6 millions d'euros, renforçant sa position financière jusqu'en juin 2025. Les actionnaires soutiennent la levée de fonds pour NOX-A12 et NOX-E36 Augmentation De Capital Offre Publique TME Pharma NOX-A12 NOX-E36
BRIEF published on 12/04/2024 at 19:55, 1 year 8 months ago TME Pharma annonce une mise à jour stratégique et un plan de financement de 2,6 millions d'euros Stratégie D'entreprise Offre Publique Plan De Financement Développement Du NOX-A12 Priorité Aux Actionnaires
BRIEF published on 12/04/2024 at 19:55, 1 year 8 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 8 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une nouvelle stratégie et un financement garanti de 2,6 millions d'euros pour ses projets NOX-A12 et NOX-E36 jusqu'en juin 2025 Financement Offre Publique TME Pharma NOX-A12 NOX-E36
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 8 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 8 months ago TME Pharma présente ses résultats sur NOX-A12 dans le glioblastome Thérapie Contre Le Cancer Glioblastome NOX-A12 Inhibition Du Point De Contrôle Immunitaire Microenvironnement Tumoral
BRIEF published on 11/23/2024 at 10:59, 1 year 8 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 8 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la présentation d'un poster par le National Cancer Institute américain sur l'inhibition de CXCL12 par NOX-A12 dans le glioblastome à la réunion annuelle du SNO 2024 Glioblastome TME Pharma NOX-A12 National Cancer Institute Inhibition
Published on 08/14/2026 at 00:15, 1 hour 15 minutes ago Corporate Update - QCM Property Exploration Update
Published on 08/13/2026 at 22:38, 2 hours 52 minutes ago Predictiv AI Announces Debt Settlement and Provides Additional Details of Previously Announced Consulting Agreement With Aktien Media Inc.
Published on 08/13/2026 at 19:55, 5 hours 35 minutes ago NuRAN Wireless Receives Nasdaq Approval to List on The Nasdaq Capital Market; Trading Expected to Commence August 17, 2026 and C$7.6 Million Financing to Close August 14, 2026
Published on 08/13/2026 at 17:55, 7 hours 35 minutes ago Alset AI Announces Agreement to Sell 9.9% Interest in Lyken AI Computing to FingerMotion
Published on 08/13/2026 at 14:31, 10 hours 59 minutes ago Wi2Wi Announces Strategic Equipment Investments to Expand Production Capacity
Published on 08/13/2026 at 23:20, 2 hours 10 minutes ago DeFi Technologies Inc. Announces Second Quarter 2026 Financial Results with Revenue of $7.8 Million, Operating Loss of $2.3 Million, and Maintained Strong Balance Sheet
Published on 08/13/2026 at 22:56, 2 hours 34 minutes ago BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING AND CONCURRENT SHARE REPURCHASE
Published on 08/13/2026 at 18:17, 7 hours 13 minutes ago EQS-Adhoc: Energiekontor AG: Energiekontor adjusts earnings guidance for the 2026 financial year
Published on 08/13/2026 at 18:00, 7 hours 30 minutes ago Deutsche EuroShop reports good operational performance in the first half of 2026 and confirms its forecast
Published on 08/13/2026 at 18:00, 7 hours 30 minutes ago Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 2 days 7 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 2 days 7 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 3 days 7 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 3 days 7 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
